STAQ Pharma Inc. recalled Hydromorphone HCL PF injections on October 9, 2025, due to incorrect or missing lot and expiration dates. The recall affects products distributed nationwide across the U.S. Healthcare providers and consumers must immediately cease using the affected medication.
Labeling: Incorrect or Missing Lot and/or Exp Date
Consumers and healthcare providers should stop using this product immediately. Contact STAQ Pharma, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, distributed in 50 mL syringes. The affected lot number is 25104595A, with an expiration date of December 27, 2025.
The product poses a significant risk due to incorrect or missing labeling. This can lead to the administration of expired or incorrect dosages, heightening the risk of adverse effects.
As of now, there are no reported incidents or injuries related to this recall. The high hazard classification indicates a serious potential risk.
Stop using the recalled product immediately. Contact STAQ Pharma, Inc. or your healthcare provider for further guidance and instructions.
For more information, call STAQ Pharma, Inc. or visit their website. Refer to the FDA recall notice for additional details.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.